ABSTRACT
INTRODUCTION Plasma Aβ42/40 ratio can be used to help predict amyloid PET status, but its clinical utility in Alzheimer’s disease (AD) assessment is unclear.
METHODS Aβ42/40 ratio was measured by LC-MS/MS in 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and 6,192 consecutive clinical specimens submitted for Aβ42/40 testing.
RESULTS High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs negative Aβ-PET results. Assuming a moderate prevalence of Aβ-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients’ cognitive impairment and help reduce PET evaluation by about 40%.
DISCUSSION Using high-throughput plasma Aβ42/40 LC-MS/MS assays can help reduce PET evaluations in patients with low likelihood of AD pathology, allowing for cost savings.
Highlights
A new plasma LC-MS/MS assay for the Aβ42/Aβ40 ratio has clinical utility in AD assessment.
Performance was assessed using specimens with a moderate prevalence of Aβ-PET positivity.
Analysis was extrapolated to 6,192 consecutive clinical specimens submitted for ratio testing.
Assay cutpoints were proposed to help suggest clinical management decisions.
Based on the assay’s high NPV, costly PET evaluations may be avoided for many individuals.
Systematic Review Aβ42/Aβ40 ratio data were analyzed from 250 ADRC cohort participants and 6,192 plasma specimens submitted for Aβ42/40 ratio testing by LC-MS/MS at Quest Diagnostics.
Interpretation Based on its high NPV, the assay identifies individuals likely to have negative amyloid PET results. Higher discriminatory power and larger fold-changes between PET-positive and negative individuals were observed compared with previous studies. Our “real-world” data set, combined with known performance characteristics, allows us to suggest cutpoints and clinical decisions based on plasma Aβ42/40 ratios.
Future Directions Longitudinal plasma specimens from individuals who convert from PET-negative to positive, or that transition from cognitively normal to MCI and AD, will improve understanding of the prognostic utility of the Aβ42/40 ratio. Using Aβ42/40 ratio alone or combined with other biomarkers, to follow patients with cognitive impairment may yield insights regarding their disease conditions and progression and who may benefit from disease-modifying therapeutics.
Competing Interest Statement
Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, and Michael K. Racke are employees of Quest Diagnostics. All other authors have nothing to disclose.
Clinical Trial
This study is of a new plasma LC-MS/MS assay for the Aβ42/Aβ40 ratio
Funding Statement
Funding for this work was provided by National Institutes of Health (NIH) Center Core Grant P30AG066506 (TEG) and NIH Research Grants R01NS052318 and R01NS075012 (DEV).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Mount Sinai Medical Center IRB, and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
